<DOC>
	<DOCNO>NCT00375596</DOCNO>
	<brief_summary>This study evaluate safety efficacy new allergy medication</brief_summary>
	<brief_title>A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis</brief_title>
	<detailed_description>Study withdraw prior determine study detail</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Vasoconstrictor Agents</mesh_term>
	<criteria>Be least 6 year age , race , either gender . Have positive allergic history ocular allergy positive skin test reaction cat hair/dander , ragweed , tree and/or grass pollen within past 24 month . Have calculate bestcorrected visual acuity 0.6 logMar good eye measure use ETDRS chart . Positive bilateral CAC reaction Visit 1 &amp; 2 . Have know contraindication , allergy , sensitivity use study medication , component . Any ocular condition , opinion investigator , could affect subject 's safety trial parameter Manifest sign symptom clinically active allergic conjunctivitis either eye baseline slitlamp exam visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>